NPHC · XBRL financial data
Nutra Pharma financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (NPHC's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 |
| Cost of revenue | — | — | — | — | — | year only | — | — | — | — | — | — |
| Cost of goods and services sold | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 |
| Gross profit | 0 | — | 0 | 0 | 0 | — | 0 | 0 | 0 | — | 0 | 0 |
| Selling, general and administrative | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | — | — | — |
| Total operating expenses | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 |
| Operating income (loss) | (0) | (0)* | (0) | (0) | (0) | (0)* | (0) | (0) | (0) | (0)* | (0) | (0) |
| Interest expense | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 |
| Net income (loss) | (0) | (0)* | (0) | (0) | (0) | (0)* | (1) | 0 | (1) | (0)* | (0) | (4) |
| Earnings per share, basic USD per share | 0.00 | 0.00* | 0.00 | 0.00 | 0.00 | 0.00* | 0.00 | 0.00 | 0.00 | 0.00* | 0.00 | 0.00 |
| Earnings per share, diluted USD per share | 0.00 | 0.00* | 0.00 | 0.00 | 0.00 | 0.00* | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Weighted average shares, basic millions of shares | 7,613 | 7,622* | 7,643 | 7,657 | 7,657 | 7,736* | 7,677 | 7,743 | 7,816 | 7,876* | 8,011 | 8,067 |
| Weighted average shares, diluted millions of shares | 7,613 | 7,622* | 7,643 | 7,657 | 7,657 | 7,736* | 7,677 | 37,728 | 7,816 | — | 8,011 | 8,067 |
Balance sheet
CSVFiscal quarters (NPHC's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Short-term investments | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts receivable | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prepaid and other current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total current assets | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Property and equipment, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Right-of-use asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Total assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Accounts payable | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Accrued liabilities | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Current portion of long-term debt | — | 8 | — | — | 8 | 8 | 9 | 9 | 10 | 10 | 10 | 12 |
| Total current liabilities | 14 | 14 | 15 | 15 | 15 | 15 | 17 | 17 | 17 | 17 | 18 | 22 |
| Long-term debt | — | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lease liability, non-current | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — |
| Total liabilities | 14 | 14 | 15 | 15 | 15 | 15 | 17 | 17 | 17 | 17 | 18 | 22 |
| Accumulated deficit | (75) | (75) | (75) | (76) | (76) | (76) | (78) | (77) | (78) | (78) | (79) | (83) |
| Total stockholders' equity | (14) | (14) | (14) | (15) | (15) | (15) | (16) | (16) | (16) | (17) | (17) | (21) |
| Total liabilities and equity | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Common shares outstanding (cover page) millions of shares | 7,100 | 7,100 | 7,100 | 7,100 | 7,100 | 7,160 | 7,160 | 7,160 | 7,160 | 7,160 | 7,160 | 7,160 |
Cash flows
CSVFiscal quarters (NPHC's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (0) | (0)* | (0) | (0) | (0) | (0)* | (1) | 0 | (1) | (0)* | (0) | (4) |
| Stock-based compensation | — | — | — | — | — | — | — | 0 | 0 | 0* | 0 | 0* |
| Net cash from operating activities | (0)* | (0)* | (0) | (0)* | 0* | (0)* | (0) | (0)* | (0)* | (0)* | (0) | (0)* |
| Purchases of property and equipment | — | — | — | — | — | — | 0 | 0* | 0* | 0* | — | — |
| Net cash from investing activities | 0* | 0* | — | — | 0* | 0* | (0) | (0)* | 0* | 0* | — | — |
| Net cash from financing activities | 0* | 0* | 0 | 0* | (0)* | 0* | 0 | 0* | 0* | 0* | 0 | 0* |
| Net change in cash | — | — | — | — | — | year only | (0) | 0* | (0)* | 0* | 0 | (0)* |
Compare with peers
SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Nutra Pharma | not reported | 0 | (0.3)* | 7.2B | 0.1 quarters | 10-QJun 30, 2026 |
| International Stem Cell | 1.1 | 2.7 | 0.2* | 8.0M | — | 10-QJun 30, 2026 |
| Emmaus Life Sciences | 2.8 | 6.3 | 1.7* | 70.2M | — | 10-QJun 30, 2026 |
| Mosaic ImmunoEngineering | 0 | not reported | (0)* | 7.2M | 0.6 quarters | 10-QJun 30, 2026 |
| Avenue Therapeutics | 1.9 | 0 | (0.5)* | 3.3M | 4.1 quarters | 10-QJun 30, 2026 |
| China Foods Holdings | 0 | 0 | (0.1)* | 20.3M | 0.2 quarters | 10-QJun 30, 2026 |
| Hepion Pharmaceuticals | 1.6 | not reported | (1.4)* | 90.2M | 1.2 quarters | 10-QJun 30, 2026 |
| America Great Health | 0 | 0 | 0* | 21.2B | — | 10-QMar 31, 2026 |
| Twinlab Consolidated Holdings | 0 | not reported | (0.9)* | 259.1M | 0.0 quarters | 10-KDec 31, 2024 |
Not investment advice. Not affiliated with the U.S. SEC.